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Abstract 
The umbilical cord offers a source of readily available mesenchymal stromal cells for use in 
research and ultimately therapeutic application. However, methods of isolating these cells 
vary between investigators, and no standard method has been adopted. The aims of this work 
were to i) develop a methodology for the isolation of umbilical cord matrix cells without the 
use of enzymatic digestion or complicated dissection; ii) investigate the use of pooled 
maternal serum as a media supplement; and iii) to demonstrate that the cells isolated were 
mesenchymal stromal cells. 
 
We have demonstrated that incubating tissue explants of less than 2mm3 in serum for an 
hour, followed by the gradual addition of serum containing culture medium can increase cell 
yield compared to incubation in serum containing culture medium alone. More importantly, 
our method demonstrated that the use of pooled serum from women > 37 weeks pregnant 
(pooled maternal serum) yields higher cell numbers than the use of fetal bovine serum or 
pooled umbilical cord serum. Irrespective of the type of serum used the isolated cells were 
mesenchymal stromal cells according to the minimal criteria set out by the Mesenchymal and 
Tissue Stem Cell Committee of the International Society for Cellular Therapy.   
 
In conclusion, maternal serum has the potential to be used as an alternative to FBS for 
isolation and expansion of umbilical cord MSCs for clinical purposes.   
 
 
 
 
 
Impact Statement 
The umbilical cord is a source of readily available MSCs for use in research and ultimately 
therapeutic application. However, alternative serum sources to FBS are needed to maximise the use of 
MSCs for clinical purposes. This paper demonstrates that pooled serum from women > 37 weeks 
pregnant (pooled maternal serum) could be used as an alternative for isolation and expansion of 
UCMSCs, as it avoids the issues surrounding the use of FBS. It is also shown to be more effective 
than FBS and cord serum in producing a larger yield of MSC’s, which is promising for future stem 
cell therapy.  
 
 
  
1 Introduction 
The umbilical cord matrix or Wharton’s Jelly which surrounds the two umbilical arteries and 
one umbilical vein, is known to contain mesenchymal stromal cells (MSCs) [1,2]. MSCs are 
spindle shaped cells that have the ability to self-renew, and to undergo osteogenic, 
adipogenic, chondrogenic, myogenic, and stromal cell differentiation, demonstrating a high 
degree of plasticity [3-5]. Given the interest in the use of MSCs in regenerative medicine and 
the ethical challenges imposed by embryonic stem cells, the umbilical cord offers a readily 
available source of MSCs for use in both basic research to better understand human MSC 
biology, and in therapeutic applications.  
 
Many different methods of isolating MSCs from umbilical cord have been investigated, and 
no standard method has been adopted. The main differences in methods used are associated 
with whether or not the blood vessels were drained and/or removed, whether enzymatic 
treatment was used, the methods of harvesting Wharton’s jelly, and the culture approach used 
(either culture of the tissue or of the isolated cells). There is some variation in the culture 
media used but Dulbecco’s Modified Eagle’s Medium (DMEM) is typical. 
 
Compounding the variation in methods used to isolate the cells are the different MSC 
characterisation methods used, especially prior to 2006. In 2006 the minimal criteria to define 
human MSCs were set out by the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy (ISCT) [6]. The three minimal criteria are: 1. 
plastic adherence; 2. expression of certain surface markers - at least 95% of the cell 
population must express CD73, CD90, and CD105, and less than 2% of the cell population 
can express CD14 or CD11b, CD34, CD45, CD79α or CD19, and HLA class II (HLA-DR); 
and 3. differentiation potential – as a minimum the cells must be able to undergo osteogenic, 
adipogenic, and chondrogenic differentiation. Since 2006 a number of investigators refer to 
these minimal criteria to define umbilical cord MSCs [7-11].  
 
Although different methods of isolating and characterising MSCs from umbilical cord have 
been investigated, more recently, isolation methods have been referred to generally as either 
“enzymatic” or “explant” [8, 12, 13]. Still, no standard method has been adopted as being the 
most effective. Different groups have adapted their own methods to suit their style of 
working. Some of these methods involve quick isolation of cells, but complicated methods of 
digestion [1, 7, 9, 14]. Others involve dissection of the umbilical cord by removal of blood 
vessels [10, 12, 15, 16]. Two important factors to consider when choosing an isolation 
method are cell yield and the time taken to achieve a desirable cell yield; these must be well 
balanced for therapeutic gain.  
 
Recently, it has been highlighted that there is a need to find alternatives to FBS for use as a 
media supplement for MSC culture, due to the risk of transmitting pathogens that may cause 
viral infections and bacterial infections, transmission of prions, inflammatory reactions due to 
contamination with bovine proteins, and ethical issues with collection of animal products [11, 
12, 15, 17]. Alternatives have been considered: MSCs have been cultured successfully in 
autologous [18, 19] and non-autologous [20, 21] human serum, human platelet lysate [12, 17, 
20], autologous cord blood serum [20, 22], and autologous cord blood platelet rich plasma 
[23, 24]. Serum is collected from whole blood after it is left for a specific set time to clot and 
is then subsequently centrifuged [25, 26]. Special blood tubes are available for serum 
collection containing no anticoagulants, and plasma collection containing anticoagulants [26]. 
Plasma is collected from whole blood by centrifugation, which can be followed by a further 
centrifugation to remove platelets [26, 27]. Platelet rich plasma is produced when the platelet 
pellet is re-suspended in the plasma after centrifugation [27, 24]. Platelet lysate is produced 
when the platelet rich plasma is taken through a number of freeze thaw cycles [25, 28, 29]. 
To our knowledge serum taken from the blood of the Mother has not been investigated as a 
culture supplement for umbilical cord MSCs. 
 
Here, the aims were to: i) optimise a protocol for the isolation of umbilical cord matrix MSCs 
without the use of complicated digestion or dissection methods; ii) investigate the use of 
pooled maternal serum as a media supplement for isolation and culture of umbilical cord 
matrix MSCs; and iii) to demonstrate that the isolated cells are MSCs as defined by the 
Mesenchymal and Tissue Stem Cell Committee of the ISCT. 
 
 
2 Materials and Methods 
2.1 Ethics and Samples 
Umbilical cords and umbilical cord blood were collected from women undergoing elective 
caesarean section at full-term (>37 weeks of gestation) at Singleton Hospital, Swansea. 
Women undergoing elective section for fetal or maternal anomalies were not recruited 
therefore samples were typically from women scheduled for caesarean section due to breech 
presentation, cephalo-pelvic disproportion or emergency caesarean section at previous 
delivery. Maternal blood was collected from women in the 1-3 days leading up to their 
elective caesarean section. All samples were collected with informed written consent and 
ethical approval was obtained from the South West Wales Research Ethics Committee (REC 
No. 11/WA/0040). Serum was prepared by collecting blood into serum separation tubes 
(Greiner Bio-one, Gloucestershire, UK), allowing clotting for 90 minutes and centrifugation 
to collect serum which was aliquoted and stored frozen at -80oC. After centrifugation, 
samples were processed aseptically in a class II tissue culture cabinet.  
 
2.2 Umbilical Cord Collection and Preparation 
The placenta was collected at elective caesarean section and a 10 - 12cm long piece of 
umbilical cord proximal to the placenta was excised within two hours of delivery. This was 
washed in phosphate buffered saline (PBS; Life Technologies, Paisley, UK) two to four times 
to remove excess blood. The piece of cord was then placed in Hank’s balanced salt solution 
(HBSS; Life Technologies) and kept in the refrigerator until processing (two hours).  
 
2.3 Optimising MSC Isolation Protocol  
2.3.1 Size of Umbilical Cord Explants 
An explant approach was taken to isolate MSCs from the umbilical cord. The effect on MSC 
yield of explant size at the initiation of culture was investigated first. Segments of cord 
measuring 2cm were cut in half. Each pair of halves were then cut into (i) six pieces of equal 
size, (ii) ten pieces of equal size, or (iii) multiple small pieces measuring <2mm3. Pieces 
generated from each half were placed into individual T25 tissue culture flasks (2 flasks/tissue 
size; Greiner Bio-One) with 4ml low glucose, phenol red free Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 1% glutamax, 10% Fetal Bovine Serum (FBS), 1% 
penicillin streptomycin fungisone (PSF) (100U/ml penicillin, 100µg/ml streptomycin and 
0.25µg/ml amphotericin B), and 0.1% non-essential amino acids (NEAA) (all Life 
Technologies), hereafter called complete DMEM. This was designated as day 0. On day 2 an 
extra 2ml of the same medium was added to each flask.  
 
In parallel, another 2cm segment of umbilical cord was cut in half, each half was chopped 
into small pieces (<2mm3), placed into T25 flasks, and 500µl of FBS was added. An hour 
later 1ml complete DMEM medium was added to each flask (designated day 0). A further 
1ml of medium was added to the flasks every day until day 5.   
  
On day 8 the tissue and medium were removed from all flasks, the flasks were rinsed with 
PBS (Life Technologies), and fresh medium was added. On day 15 the cells were harvested 
and counted (see below).   
 
2.3.2 Serum Used 
FBS was compared with umbilical cord blood serum (CS) and pooled serum prepared from 
peripheral blood of women >37 weeks pregnant (pooled maternal serum; MS). Umbilical 
cord serum [20, 22], umbilical cord platelet rich plasma [23, 24] and human serum (not from 
pregnant donors) [18, 20, 21] have been reported elsewhere as a supplement in MSC isolation 
media. Segments of cord measuring 1cm were cut in half, each half was chopped into small 
pieces (<2mm3), and the small pieces were placed into 6 well plates. FBS, CS, or MS was 
then added 250µl/well in duplicate (not paired cord halves). After 1hr, 500µl low glucose 
phenol red free DMEM supplemented with 10% FBS, CS, or MS (+ glutamax, PSF, and 
NEAA as above) was added and then 500µl every day until day 3, to give a final volume of 
2ml in each well. On day 8 the tissue and medium were removed, each well was rinsed with 
PBS, and fresh corresponding medium was added. On day 15 the cells were harvested and re-
seeded in T25 culture flasks (one well to one T25 flask). On day 18 the cells were harvested 
and counted. 
 
2.4 Cell Harvesting and Counting 
For harvesting, the cells were first rinsed with PBS to remove any remaining medium and 
then detached using 0.05% Trypsin/EDTA (Life Technologies) at 37°C for 8 to 10 minutes. 
Trypsin was neutralised by the addition of FBS containing medium. The cells were pelleted 
by centrifugation at 400 x g for 5 minutes. Cells were re-suspended in complete medium and 
counted using a C-Chip disposable haemocytometer (Labtech International, East Sussex, 
UK).   
 
2.5 Cell Cryopreservation and Resuscitation 
Cells were cryopreserved in 1ml of 10% DMSO (Sigma-Aldrich, Dorset, UK) in complete 
DMEM with 1x106 cells per vial. Cryopreservation vials (2ml, Greiner Bio-One) were placed 
in a Nalgene cryopreservation 1ºC freezing container (Thermo-Scientific, Leicestershire, UK) 
containing 250ml of 2-propanol (Sigma-Aldrich) at -80°C for 24 hours with a decrease in 
temperature of 1ºC/min. The vials were then transferred to liquid nitrogen storage. 
 
For cell resuscitation, vials were removed from liquid nitrogen and warmed media was added 
to the vials gradually to thaw the cell suspension. Once thawed, the cell suspensions were 
transferred to larger vessels containing warmed medium. The cells were then pelleted by 
centrifugation at 400 x g for 5 minutes to remove any DMSO. 
 2.6 Cell Characterisation  
2.6.1 Cell Surface Phenotype by Flow Cytometry 
The phenotype of previously cryopreserved cells isolated using FBS, CS, and MS were 
investigated by incubating 1x105 cells with antibodies shown in Table 1 (all from 
eBioscience, Hatfield, UK) including markers used for phenotyping as set out by the ISCT 
[6] and an unstained control. The cells were incubated with pre-optimised concentrations of 
antibody in the dark on ice for 30 minutes. After washing the cells with 0.2% BSA/0.05% 
sodium azide in PBS, the cells were fixed (BD Cytofix; BD Biosciences, Oxford, UK) and 
acquired on a flow cytometer (FACS Aria I; BD Biosciences) within 24 hours. Compensation 
was conducted using single stained cells for each fluorochrome used. Analysis of acquired 
data was undertaken using Kaluza Flow Cytometry Analysis software (version 1.2, Beckman 
Coulter). The signal indices were calculated by dividing the median fluorescence of the 
stained cells by the median fluorescence of the unstained cells. 
 
2.6.2 Differentiation 
2.6.2.1 Adipogenesis 
Cells were seeded at 3x103 cells per cm2 in a 24 well plate. After 5 days of culture the media 
was removed and replaced with 500µl/well adipogenesis differentiation medium (Adipocyte 
Differentiation Basal Medium supplemented with 10% Adipogenesis supplement, 1% PSF 
Life Technologies). The media was replaced every 3 to 4 days. On day 16 the cells were 
fixed with 4% paraformaldehyde (Sigma-Aldrich) and stained with Oil Red O staining 
solution (300mg Oil Red O powder (Sigma-Aldrich) in 100ml 99% isopropanol (Fisher 
Scientific); 6ml of this solution was added to 4ml of distilled water, incubated for 10 minutes 
at room temperature then filtered through Whatman filter paper (Whatman International, 
Maidstone, UK)). 
 
2.6.2.2 Chondrogenesis 
Cells were seeded at 1x105 cells in 5µl droplets of low glucose phenol red free complete 
DMEM in the centre of a well in a 24 well plate. After 2 hours, 500µl/well chondrogenesis 
differentiation medium (Chondrocyte Differentiation Basal Medium supplemented with 10% 
Chondrogenesis supplement, 1% PSF; Life Technologies) was added. The media was 
replaced every 2 to 3 days. On day 23 the cells were fixed with 4% paraformaldehyde 
(Sigma-Aldrich) and stained with Alcian Blue staining solution (1mg Alcian Blue powder 
(Sigma-Aldrich) in 99ml 0.1N hydrochloric acid, HCl (Sigma-Aldrich)).   
 
2.6.2.3 Osteogenesis 
Cells were seeded at 6x103 cells per cm2 in a 24 well plate. After 4 days of culture the media 
was removed and replaced with 500µl/well osteogenesis differentiation medium (Osteocyte 
Differentiation Basal Medium supplemented with 10% Osteogenesis supplement, 1% PSF; 
Life Technologies). The media was replaced every 3 to 4 days. On day 25 the cells were 
fixed with 4% paraformaldehyde (Sigma-Aldrich) and stained with Alizarin Red S staining 
solution (2g Alizarin Red S powder (Sigma-Aldrich) in 100ml distilled water and the pH was 
adjusted to 4.2).  
 
2.7 Statistical Analysis 
Paired t-tests and ANOVA were performed on the results of the MSC isolation experiments 
using the SPSS statistical software package (version 19, IBM). A p-value <0.05 was 
considered significant. 
 
 
3 Results 
3.1 Optimising the Isolation Protocol – Size of Umbilical Cord Explants 
The number of putative MSCs isolated from the umbilical cord increases with decreasing size 
of the tissue explants (Figure 1). However, the only significant difference (for pieces + 
media) was between 10 pieces of tissue and 6 pieces of tissue (p=0.041; n = 3). Seeding < 
2mm3 explants of tissue onto 500µl FBS and then increasing the total volume of media in the 
flask gradually over the next 5 days yielded significantly more putative MSCs than seeding 
explants of the same size directly with 4ml media (p=0.011; n = 3; Figure 1).  
  
3.2 Optimizing the Isolation Protocol – Serum Used 
Having shown that seeding small explants onto a bed of FBS rather than into 4 ml complete 
medium increased the yield of putative MSCs, the possibility that different serum substrates 
might further improve cell yield was investigated. The substrates chosen were umbilical cord 
serum and pooled maternal serum prepared from women who were > 37 weeks pregnant. The 
use of pooled maternal serum gave the greatest yield of cells (Figure 2); significantly more 
than FBS (p = 0.004; n = 3) and more than cord serum but not significantly so (p = 0.065; n = 
3). 
 3.3 Characterisation of Umbilical Cord Matrix-Derived Cells 
3.3.1 Plastic Adherence 
Irrespective of the substrate used for seeding and culture (FBS, cord serum, pooled maternal 
serum) the cells derived from the umbilical cord matrix explants were plastic adherent and 
had a fibroblast-like structure on day 18 (Figure 3). 
 
3.3.2 Phenotype Marker Panel by Flow Cytometry 
To confirm that irrespective of the serum used the cells isolated were MSCs, cell phenotypes 
were studied using flow cytometry. The cells isolated using FBS, umbilical cord serum, or 
pooled maternal serum were all negative for CD14, CD19, CD34, CD45, and HLA-DR 
(Figure 4a) and were all positive for CD73, CD90, and CD105 (Figure 4b). Overall there 
were no differences in the level of expression of these markers on MSCs isolated using 
different sera with the exception of CD105 which was significantly higher on cells isolated 
using umbilical cord serum (p=0.047; ANOVA; Figure 4c).  
 
3.3.3 Differentiation 
Cells isolated using FBS, umbilical cord serum, and pooled maternal serum were all able to 
undergo adipogenesis, chondrogenesis, and osteogenesis (Figure 5). 
 
Table 2 summarises the characterisation results for the cells isolated using each of the three 
sera confirming that they match the minimal criteria for MSCs as set out by the Mesenchymal 
and Tissue Stem Cell Committee of the ISCT [6]. 
  
4 Discussion 
Here we describe an explant method for isolation of MSCs from human umbilical cord 
matrix. The smaller the explant the greater the yield and seeding the explants on serum and 
gradually increasing the culture volume also enhanced yield. On comparing serum sources – 
fetal bovine serum, umbilical cord blood serum, or serum from women > 37 weeks pregnant 
– the latter gave the greatest yield of MSCs. Irrespective of the serum source used for seeding 
and media supplementation, the cells isolated from small explants of umbilical cord met the 
minimal criteria for MSCs based on surface marker expression and differentiation potential 
[6]. 
 
There is a belief that the minimal criteria set out by the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy are no longer a robust enough 
method of determining MSC authenticity [30], as they could be used to characterise 
fibroblastic cell strains [31]. Moreover, there are reports in the literature supporting a theory 
that transplanted MSCs themselves do not differentiate to form new tissue in vivo, but rather 
migrate to a site of injury or disease and secrete factors which stimulate the resident stem 
cells to construct new tissue [32].  This is clearly an important area for further research.  
 
Nevertheless, the minimum criteria of the ISCT are still being used to define MSCs [33] as 
there have been no new guidelines set out for MSC characterisation. It is important to note, 
therefore, that even though our cells have met the minimal criteria, the true in vivo 
differentiation potential of these isolated cells remains unknown and is worth further 
investigation. 
 
We have also demonstrated here that the cells met the minimum criteria through 
identification as being CD34 negative. There have been reports stating that MSCs are in fact 
CD34 positive [34, 35]. However, these reports also state that it has been demonstrated that 
any tissue resident CD34 positive cells lose their expression after expansion in culture, which 
would account for our CD34 negative result. There may be CD34 positive MSCs within the 
umbilical cord matrix, but so far none have been identified. 
 
An explant approach was chosen to avoid the limitations of introducing tissue digestion 
enzymes into the isolation procedure. The number of cells isolated from the umbilical cord 
increased with decreasing size of the tissue explants so that small pieces measuring < 2mm3 
yielded the most. This approach likely increases the tissue surface area and enables more 
cells to migrate out of the tissue and onto the plastic surface of the culture flasks. Other 
authors similarly minced or cut the tissue into small pieces or fragments measuring around 1-
5mm2 [5, 12, 16]. We found that cell yield could be increased further when the explants were 
first seeded onto a small volume of FBS for an hour, followed by the gradual addition of 1ml 
of medium each day rather than immediate seeding into culture media. The most likely 
explanation for this is exposure to increased concentrations of key factors, such as 
chemokines or growth factors, in the serum. 
 
Given the need for alternative supplements to FBS for MSC culture, FBS was compared to 
cord serum and serum prepared from pregnant women (> 37 weeks pregnant; full-term). 
After 18 days of culture, explants seeded on and cultured in pooled maternal serum yielded 
more cells than either FBS or cord serum. This would suggest that pooled maternal serum 
draws more cells from the explant and/or has a greater proliferative effect on the cells than 
FBS or cord serum, at least in the short term. While there are no reports comparing relevant 
mediator levels in FBS, cord, and serum from pregnant women a number of studies highlight 
differences between serum from pregnant and not pregnant women. For example, TGFß1 is 
elevated in pregnant versus not pregnant women [36] and it would be worthwhile extending 
this phenotype to growth factors and cytokines with a role in MSC proliferation.      
 
Alternative serum sources to FBS are needed to maximise the use of MSCs for clinical 
purposes, due to the risk of contamination, inflammatory reactions, and ethical issues [11, 12, 
15, 17]. Alternative supplements have been used successfully, such as human serum [18-21], 
human platelet lysate [12, 17, 20], cord blood serum [20, 22], and cord blood platelet rich 
plasma [23, 24]. The difference between serum and platelet rich plasma is that serum is 
collected from centrifuged whole blood which was left to clot [25, 26], whereas platelet rich 
plasma is collected when un-clotted whole blood is centrifuged, the plasma is removed, and 
the platelet pellet is re-suspended in the plasma [26, 27, 24]. To our knowledge, the use of 
maternal blood serum has not been investigated. We now show that serum prepared from the 
blood of full-term pregnant women, with further investigation, has the potential to be an 
alternative to FBS for isolation and expansion of umbilical cord MSCs for clinical purposes. 
The use of serum prepared from the blood of full-term pregnant women would be more 
convenient than cord serum, especially where delayed cord clamping is employed.  Its use 
does, however, pose other potential problems because the invasive nature of collection limits 
the volumes available from any one pregnant woman. Pooling of samples could overcome 
this, however, any immunological effects on the cells of pooling samples from different 
women would have to be investigated. Also, investigation of why serum from pregnant 
women had this effect is warranted and might identify a growth factor mix that could be used 
instead.    
 
In conclusion, we have developed an umbilical cord matrix MSC isolation approach using 
small explants first seeded on pooled maternal serum and then cultured in medium containing 
the same serum, which yields cells that meet the criteria of MSCs. While pooled maternal 
serum gives the greatest yields, further work is required including detailed investigation of 
how this affects MSC phenotype and function, especially the immunomodulatory properties 
of these cells. Further investigation is also needed into the characterising of these cells, 
including by means of an in vivo transplantation. 
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Table 1: Antibodies used for flow cytometry 
Surface antigen Fluorochrome Clone 
CD19 
CD34 
CD45 
CD73 
CD90 Thy-1 
CD14 
CD105 
HLA-DR 
PC7 
eFluor450 
APC 
FITC 
PE 
APC eFluor780 
PE 
eFluor450 
- 
4H11 
2DI 
AD2 
eBio5E10 
- 
SN6 
L243 
 Table 2: Effect of different sera selection on the minimal criteria for defining mesenchymal stromal cells as set out by 
the ISCT 
 Minimal 
Criteria 
Fetal Bovine 
Serum 
Cord Serum Pooled Maternal 
Serum 
Plastic 
Adherence 
+ + + + 
     
CD73 + + + + 
CD90 + + + + 
CD105 + + + + 
CD14 - - - - 
CD19 - - - - 
CD34 - - - - 
CD45 - - - - 
HLA-DR - - - - 
     
Adipogenesis + + + + 
Chondrogenesis + + + + 
Osteogenesis + + + + 
 
 Figure 1: The effect of umbilical cord explant size on the yield of putative mesenchymal stromal cells 
Explants of umbilical cord of varying size were cut from the cord as detailed in the Materials and Methods. Pieces were 
seeded into 4 ml complete DMEM with 2 ml additional media on day 2 or, in the case of small (<2mm3) explants + FBS, 
pieces were seeded onto 500 µl FBS then 1 ml media was added after 1 hour and every day until day 5. On day 8 the tissue 
was removed, the media was replaced, and the putative MSCs were cultured for a further 7 days before harvesting by 
trypsinisation and counting. All experiments were conducted in T25 culture flasks. Cell counts are shown as mean ± SEM. 
n=3 different umbilical cords, each in duplicate. 
 
 Figure 2: The effect of different sera used at seeding and as a medium supplement throughout culture on the yield of 
putative mesenchymal stromal cells from umbilical cord explants 
Small (<2mm3) explants of umbilical cord were seeded onto 250µl of FBS, pooled umbilical cord serum from full-term non-
laboured deliveries, or pooled serum from women > 37 weeks pregnant. After 1 hour and then each day until day 3, 500µl of 
media containing the same serum as used for seeding was added to each flask. On day 8 the tissue was removed and the 
media was replaced with fresh corresponding media. On day 15 the cells were harvested and re-seeded before harvesting and 
counting on day 18. All experiments were conducted in 6 well culture plates until day 15 and in T25 culture flasks from day 
15 – 18. Cell counts are shown as mean ± SEM. n = 3 different umbilical cords, each in duplicate. 
 
 
Figure 3: Plastic adherence of putative mesenchymal stromal cells isolated from umbilical cord explants cultured in 
three different sera 
Small (<2mm3) explants of umbilical cord were seeded onto different sera and then cultured in medium supplemented with 
the same sera as described in the Materials and Methods. On day 18, photomicrogrpahs were taken prior to harvesting and 
cryopreservation of the cells. Representative examples of 6 preparations of cells isolated using a) fetal bovine serum, b) 
umbilical cord blood serum, and c) pooled maternal blood serum are shown. 0.25mm scale bars are shown. Images were 
taken at room temperature using a Zeis Axiovert 40 microscope at x5 magnification and a Canon 1100D camera with the 
Canon EOS Utility software 
 
 a) 
 b) 
 c) 
Figure 4: Phenotype of putative mesenchymal stromal cells isolated from umbilical cord explants cultured in three 
different sera  
Small (<2mm3) explants of umbilical cord were seeded onto different sera and then cultured in medium supplemented with 
the same sera as described in the Materials and Methods. On day 18, cells were harvested and cryopreserved; the cells were 
then resuscitated and stained for flow cytometry with fluorochrome conjugated antibodies to a) CD14, CD19, CD34, CD45, 
or HLA-DR and b) CD73, CD90, or CD105. The median fluorescent intensity was used to calculate the signal index 
(calculated by dividing the median fluorescence of the stained cells by the median fluorescence of the unstained cells) and 
the mean ± SEM is shown (n=3/group) (c). 
 
 Figure 5: Differentiation of putative mesenchymal stromal cells isolated from umbilical cord explants cultured in 
three different sera  
Small (<2mm3) explants of umbilical cord were seeded onto different sera and then cultured in medium supplemented with 
the same sera as described in the Materials and Methods. On day 18, cells were harvested and cryopreserved; the cells were 
then resuscitated and adipogenesis, chondrogenesis, or osteogenesis was induced in the cells. After 16 days in adipogenesis 
differentiation medium the cells were fixed and stained with Oil Red O, shown in a), d), and g); after 23 days in 
chondrogenesis differentiation medium the cells were fixed and stained with Alcian Blue, shown in b), e), and h); after 25 
days in osteogenesis differentiation medium the cells were fixed and stained with Alizarin Red S, shown in c), f), and i). 
Representative examples of preparations of cells isolated using fetal bovine serum (a, b, and c), umbilical cord blood serum 
(d, e, and f), and pooled maternal blood serum (g, h, and i) are shown. 0.25mm scale bars are shown. Images were taken at 
room temperature using a Zeis Axiovert 40 microscope at x10 magnification and a Canon 1100D camera with the Canon 
EOS Utility software. 
 
 
 
 
